Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminomethylamide SCHEMBL10378627 | 0.87 | LMNA (0.52) | LMNAMEN1CYP1A2KMT2AADRA1A | |
| Acetic Acid SCHEMBL7064477 | 0.84 | LMNA (0.60) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Acetic Acid SCHEMBL4211515 | 0.82 | LMNA (0.57) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Acetone SCHEMBL1036956 | 0.81 | LMNA (0.63) | LMNAALOX15THRB | |
| Carbamic Acid SCHEMBL5387548 | 0.81 | LMNA (0.63) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Propionic Acid SCHEMBL8820914 | 0.81 | LMNA (0.63) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Bicarbonate SCHEMBL5374586 | 0.81 | LMNA (0.71) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Bicarbonate SCHEMBL28895866 | 0.81 | LMNA (0.71) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Bicarbonate SCHEMBL28942687 | 0.81 | LMNA (0.71) | LMNAGABRPGABRDGABRA1GABRB1 | |
| Butyric Acid SCHEMBL8820913 | 0.80 | FFAR3 (0.59) | LMNAOR51E2GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020209350-A1 | RAPID DISINTEGRATING ORAL TABLET FOR TREATMENT OF DIABETES | 田辺三菱製薬株式会社 | 2020-10-15 | — | — | WO | claimed |
| US-20120149719-A1 | BITTER TASTE MASKING DOSAGE FORM | TANIGUCHI YOICHI (JP) | 2012-06-14 | — | — | US | claimed |
| US-20100209503-A1 | Bitter Taste Masking Dosage Form | SHIONOGI & CO., LTD (JP) | 2010-08-19 | — | — | US | claimed |
| EP-1927347-A1 | BITTERNESS-REDUCING AGENT | Shionogi Co., Ltd. (JP) | 2008-06-04 | — | — | EP | claimed |
| JP-2023835-A | — | — | None | — | — | JP | disclosed |
| JP-1250095-A | — | — | None | — | — | JP | disclosed |
| JP-6157915-A | — | — | None | — | — | JP | disclosed |
| JP-9087169-A | — | — | None | — | — | JP | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-116546978-A | Delayed and sustained release oral pharmaceutical dosage forms of JANUS kinase (JAK) inhibitors and methods of use thereof | 南京三迭纪医药科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230240999-A1 | NOVEL FINE PARTICLE COATING (DRUG-CONTAINING HOLLOW PARTICLE AND METHOD FOR MANUFACTURING SAME) | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-03 | — | — | US | disclosed |
| JP-H0987169-A | COATED CAPSULE PREPARATION OF DIGESTIVE TRACT LOWER PART RELEASE TYPE | TANABE SEIYAKU CO LTD | 1997-03-31 | — | — | JP | disclosed |
| EP-0508756-B1 | Stabilized vitamin D preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5487900-A | Stabilized vitamin D preparation | TAKEDA CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-01-30 | — | — | US | disclosed |
| JP-H06157915-A | HARD COATING FILM COMPOSITION FOR CAPSULE | WARNER LAMBERT KK | 1994-06-07 | — | — | JP | disclosed |
| EP-0508756-A1 | Stabilized vitamin D preparation | Takeda Chemical Industries, Ltd. (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0409254-A1 | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
| JP-H0223835-A | COATING AGENT FOR PHYSIOLOGICALLY ACTIVE SUBSTANCE FOR RUMINANT AND ADDITIVE OF FEED THEREFOR | KYOWA HAKKO KOGYO CO LTD | 1990-01-26 | — | — | JP | disclosed |
| JP-H01250095-A | ORIGINAL LIQUID COMPOSITION FOR PRODUCING SPHERICAL NUCLEAR FUEL PARTICLE AND PRODUCTION OF SPHERICAL NUCLEAR FUEL PARTICLE BY USING THIS COMPOSITION | NUCLEAR FUEL IND LTD | 1989-10-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | LMNA 2193/4885GLRA1 3881/4885SLC6A9 3949/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | LMNA 2193/4885GLRA1 3881/4885SLC6A9 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.